Summit Therapeutics (SMMT) Assets Average (2020 - 2025)
Summit Therapeutics (SMMT) has disclosed Assets Average for 6 consecutive years, with $292.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Assets Average fell 30.65% year-over-year to $292.9 million, compared with a TTM value of $292.9 million through Sep 2025, down 30.65%, and an annual FY2024 reading of $319.3 million, down 26.36% over the prior year.
- Assets Average was $292.9 million for Q3 2025 at Summit Therapeutics, down from $353.9 million in the prior quarter.
- Across five years, Assets Average topped out at $469.2 million in Q4 2024 and bottomed at $106.1 million in Q2 2022.
- Average Assets Average over 5 years is $253.7 million, with a median of $227.9 million recorded in 2023.
- The sharpest move saw Assets Average soared 299.86% in 2023, then tumbled 58.68% in 2024.
- Year by year, Assets Average stood at $121.0 million in 2021, then surged by 238.57% to $409.7 million in 2022, then plummeted by 48.58% to $210.7 million in 2023, then soared by 122.68% to $469.2 million in 2024, then tumbled by 37.58% to $292.9 million in 2025.
- Business Quant data shows Assets Average for SMMT at $292.9 million in Q3 2025, $353.9 million in Q2 2025, and $409.7 million in Q1 2025.